Royalty and Commercial Payment Purchase Agreements (Tables)

9 Months Ended

Sep. 30, 2024

Royalty and Commercial Payment Purchase Agreements

Summary of royalty and commercial payment receivable activities

The following table summarizes the royalty and commercial payment receivable activities under the cost recovery method during the nine months ended September 30, 2024 (in thousands):

		Balance as of January 1, 2024		Acquisition of Royalty and Commercial Payment Receivables		Receipt of Royalty and Commercial Payments		Recognition of Contingent Consideration		Impairment of Royalty and Commercial Payment Receivables		Reclassification of Royalty and Commercial Payment Receivables from Cost Recovery to EIR Method		Balance as of September 30, 2024
Daré	$	—	$	22,000	$	—	$	—	$	—	$	—	$	22,000
Talphera		—		8,000		(80)		—		—		—		7,920
LadRx		6,000		—		—		1,000		—		—		7,000
Aptevo		7,976		—		(794)		—		—		—		7,182
Agenus		14,000		—		—		—		(14,000)		—		—
Aronora		9,000		—		—		—		(9,000)		—		—
Palobiofarma		10,000		—		—		—		—		—		10,000
Viracta		8,500		—		(8,500)		—		—		—		—
Kuros		4,500		—		—		—		—		—		4,500
Affitech		12,191		—		(7,396)		3,000		—		(7,795)		—
Total	$	72,167	$	30,000	$	(16,770)	$	4,000	$	(23,000)	$	(7,795)	$	58,602

The following table summarizes the royalty and commercial payment receivable activities under the EIR method during the nine months ended September 30, 2024 (in thousands):

		Balance as of January 1, 2024		Reclassification of Royalty and Commercial Payment Receivables from Cost Recovery to EIR Method		Income from Purchased Receivables Under EIR Method		Receipt of Royalty and Commercial Payments		Balance as of September 30, 2024
Affitech	$	—	$	7,795	$	9,985	$	(9,493)	$	8,287
Total	$	—	$	7,795	$	9,985	$	(9,493)	$	8,287